ADAM17、EGFR在子宫内膜癌组织中的表达及临床意义

EXPRESSION AND CLINICAL SIGNIFICANCE OF ADAM17 AND EGFR IN ENDOMETRIAL CARCINOMA

目的:探讨子宫内膜癌组织ADAM17、EGFR的表达和临床意义。方法:应用免疫组化染色法检测20例正常子宫内膜、20例不典型增生子宫内膜和50例子宫内膜癌组织ADAM17和EGFR的表达情况。结果:子宫内膜癌组织ADAM17、EGFR的阳性表达率均明显高于正常子宫内膜和不典型增生子宫内膜(P<0.01);子宫内膜癌组织ADAM17、EGFR表达与肌层浸润深度和淋巴结转移有关(P<0.05),与年龄、是否绝经无关(P>0.05);子宫内膜癌组织ADAM17与EGFR的表达呈正相关关系(r=0.691,P<0.01)。结论:ADAM17、EGFR在子宫内膜癌的发生发展和转移过程中可能起重要作用。

Objective：To investigate the expression and clinical significance of adisintegrin and metalloprotease-17 （ADAM17） and epidermal growth factor receptor （EGFR） in endometrial carcinoma. Methods： Immunohistochemical staining was used to detect the ADAM17 and EGFR expression in 20 cases of nonnal endometrium, 20 cases of atypical hyperplasia endometrium and 50 cases ofendometrial carcinoma. Results： The positive expression rate of ADAM17 and EGFR in cndornctrial carcinoma were all obviously higher than normal endometrium and atypical hyperlasia endometrium （P〈0.01）. In endometrial carcinoma, the expression of ADAM 17 and EGFR were related to muscular infiltration depth and lymph node metastasis （P〈 0.05）, but not related to age and whether menopause （P〉 0.05）. In endometrial carcinoma, the expression of ADAM 17 was positively correlated to EGFR （r=0.691, P〈0.01）. Conclusions： ADAM17 and EGFR may play important role in development and metastasis of endometrial carcinoma.